Table 1. Results of administering prophylactic HIPEC based on randomized study data.

Authors	Country	HIPEC regimen	5-year survival
Hamazoe et al. (24) (1994)	Japan	HIPEC (n=42)—10 mg/L mitomycin C in 2 L of perfusate, 40–45 °C, 50–60 min	62.4%
		Control group (n=40)	52.5%
Ikeguchi et al. (25) (1995)	Japan	HIPEC (n=78)—80–100 mg/m2 mitomycin С in 8–10 L of perfusate, 40–42 °C, 50–60 min	66%
		Control group (n=96)	44%
Fujimoto et al. (26) (1999)	Japan	HIPEC (n=71)—10 mg/L mitomycin С in 3–4 L of perfusate, 43–44 °C, 120 min	–
		Control group (n=70)	–
Yonemura et al. (27) (2001)	Japan	HIPEC (n=48)—30 mg mitomycin С + 300 mg CDDP in 6–8 L of perfusate, 42–43 °C, 60 min	61%
		Intraoperative normothermic chemotherapy (n=44)—30 mg mitomycin С + 300 mg CDDP in 6–8 L of perfusate, 37 °C, 60 min	43%
		Control group (n=47)	42%

HIPEC, hyperthermic intraperitoneal chemotherapy; CDDP, cisplatin.